Short Interest in Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Declines By 86.6%

Basilea Pharmaceutica AG (OTCMKTS:BPMUF - Get Free Report) saw a large decline in short interest during the month of March. As of March 15th, there was short interest totalling 2,100 shares, a decline of 86.6% from the February 28th total of 15,700 shares. Currently, 0.0% of the company's stock are short sold. Based on an average daily trading volume, of 100 shares, the short-interest ratio is currently 21.0 days.

Basilea Pharmaceutica Stock Performance

Shares of OTCMKTS:BPMUF remained flat at $54.00 on Friday. Basilea Pharmaceutica has a 1 year low of $38.60 and a 1 year high of $54.00. The company has a quick ratio of 3.27, a current ratio of 4.10 and a debt-to-equity ratio of 5.70. The company has a 50-day simple moving average of $52.95 and a two-hundred day simple moving average of $52.63.

Basilea Pharmaceutica Company Profile

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.